Northpond Ventures

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Established in 2019 and headquartered in Waltham, Massachusetts, Eleanor Health offers comprehensive, whole-person care for mental health and substance misuse. Its services include evidence-based outpatient care, medication-assisted treatment for addiction, and personalized recovery plans, which are delivered through a network of outpatient clinics, virtually, and in community and home settings. This integrated approach aims to expedite the recovery process for individuals suffering from substance use disorders.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Vizgen, Inc. is a biotechnology company focused on developing advanced tools for spatially resolved transcriptomic profiling, which enhances understanding of biological systems related to human health and disease. The company's primary offering, MERFISH, is a multiplexed single-molecule imaging technology that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This technology facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights for research in fields such as oncology, immunology, neuroscience, infectious diseases, and regenerative medicine. Founded in 2019 and based in Cambridge, Massachusetts, Vizgen aims to empower medical researchers to explore complex biological questions on a systems scale through its innovative profiling solutions.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Established in 2019 and headquartered in Waltham, Massachusetts, Eleanor Health offers comprehensive, whole-person care for mental health and substance misuse. Its services include evidence-based outpatient care, medication-assisted treatment for addiction, and personalized recovery plans, which are delivered through a network of outpatient clinics, virtually, and in community and home settings. This integrated approach aims to expedite the recovery process for individuals suffering from substance use disorders.

Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.

OPT Industries is a digital manufacturing company founded in 2019 by Jifei Ou in Cambridge, Massachusetts. The company specializes in designing and mass-producing precision-engineered products at the micron scale, leveraging a combination of advanced machinery, software, and design expertise. OPT Industries offers its clients the ability to develop innovative product concepts and efficiently transition them to commercialization with rapid and scalable production capabilities. By providing high-quality products with shortened lead times, the company caters to globally recognized brands seeking to enhance their offerings through precision manufacturing solutions.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Scipher Medicine is a biotechnology company that has developed a precision medicine platform aimed at improving drug therapy outcomes for patients with cardiovascular and autoimmune diseases. The company's flagship products, including PrismDx, PrismRA, and PrismUC, utilize molecular testing to predict patient responses to specific drug therapies, enabling healthcare providers to prescribe more effective treatments tailored to individual patient needs. For example, PrismRA identifies rheumatoid arthritis patients who are unlikely to respond to certain anti-TNF therapies, allowing for timely alternative treatments. By leveraging a simple blood sample to analyze RNA and generate genomic signatures, Scipher Medicine helps healthcare professionals select the most suitable therapies based on the underlying biology of diseases rather than relying on traditional classifications or symptomatic assessments. This innovative approach not only enhances patient care but also addresses significant inefficiencies in the healthcare system, reducing costs associated with ineffective treatments. Scipher Medicine, incorporated in 2013 and based in Waltham, Massachusetts, aims to transform drug prescribing and development through its advanced molecular technology.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Torus Biosystems, founded in 2019 and based in Cambridge, Massachusetts, develops a diagnostic device that enables DNA testing for scientific and medical research. The company's apparatus is designed for various applications, including consumer products, food safety for humans and animals, and sectors such as hygiene, beauty care, agriculture, horticulture, and forestry. By providing access to DNA testing for non-medical purposes, Torus Biosystems supports the advancement of research across multiple fields.

Outcomes4Me Inc. is an AI-driven healthcare platform based in Cambridge, Massachusetts, founded in 2017. It focuses on empowering cancer patients by providing access to personalized, evidence-based treatment options and clinical information. The platform enables patients to navigate their care proactively, facilitating informed decision-making and improving health outcomes. By democratizing healthcare, Outcomes4Me promotes health equity and supports deeper insights into patient care, while also accelerating research and access to innovative treatments. The company is led by a team of experienced professionals from various sectors, including healthcare, oncology, and technology, dedicated to enhancing the patient experience in cancer treatment.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

Vizgen, Inc. is a biotechnology company focused on developing advanced tools for spatially resolved transcriptomic profiling, which enhances understanding of biological systems related to human health and disease. The company's primary offering, MERFISH, is a multiplexed single-molecule imaging technology that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This technology facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights for research in fields such as oncology, immunology, neuroscience, infectious diseases, and regenerative medicine. Founded in 2019 and based in Cambridge, Massachusetts, Vizgen aims to empower medical researchers to explore complex biological questions on a systems scale through its innovative profiling solutions.

Scipher Medicine is a biotechnology company that has developed a precision medicine platform aimed at improving drug therapy outcomes for patients with cardiovascular and autoimmune diseases. The company's flagship products, including PrismDx, PrismRA, and PrismUC, utilize molecular testing to predict patient responses to specific drug therapies, enabling healthcare providers to prescribe more effective treatments tailored to individual patient needs. For example, PrismRA identifies rheumatoid arthritis patients who are unlikely to respond to certain anti-TNF therapies, allowing for timely alternative treatments. By leveraging a simple blood sample to analyze RNA and generate genomic signatures, Scipher Medicine helps healthcare professionals select the most suitable therapies based on the underlying biology of diseases rather than relying on traditional classifications or symptomatic assessments. This innovative approach not only enhances patient care but also addresses significant inefficiencies in the healthcare system, reducing costs associated with ineffective treatments. Scipher Medicine, incorporated in 2013 and based in Waltham, Massachusetts, aims to transform drug prescribing and development through its advanced molecular technology.

NanoView Biosciences is a biotechnology company that specializes in the development of technologies for the characterization of extracellular vesicles, particularly exosomes. Founded in 2015 and based in Boston, Massachusetts, the company utilizes its proprietary ExoView technology to provide high-throughput and cost-effective analysis solutions for life science researchers. NanoView's products, which include the ExoView R100 and ExoView tetraspanin, enable precise detection and multiparametric characterization of exosomes from complex biological samples such as blood, serum, plasma, and urine. In addition to its core products, the company offers custom assays, sample services, and a support platform to aid researchers in understanding the biological roles of exosomes and utilizing them as biomarkers for disease diagnosis, treatment, and monitoring.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Vizgen, Inc. is a biotechnology company focused on developing advanced tools for spatially resolved transcriptomic profiling, which enhances understanding of biological systems related to human health and disease. The company's primary offering, MERFISH, is a multiplexed single-molecule imaging technology that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This technology facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights for research in fields such as oncology, immunology, neuroscience, infectious diseases, and regenerative medicine. Founded in 2019 and based in Cambridge, Massachusetts, Vizgen aims to empower medical researchers to explore complex biological questions on a systems scale through its innovative profiling solutions.

IsoPlexis is a life science technology company based in Branford, Connecticut, founded in 2013. It focuses on developing a single-cell detection system that identifies patient immune responses at the single-cell level. This innovative platform enables the assessment of therapeutic safety and efficacy, as well as the monitoring of disease progression. IsoPlexis specializes in cell-based proteomic systems and biomarkers, providing insights into functional protein biology and cellular signaling networks with high resolution. By offering these capabilities, the company aids in predicting patient responses to novel immunotherapies and cellular therapies, ultimately enhancing therapeutic development and informing clinical decisions.

IsoPlexis is a life science technology company based in Branford, Connecticut, founded in 2013. It focuses on developing a single-cell detection system that identifies patient immune responses at the single-cell level. This innovative platform enables the assessment of therapeutic safety and efficacy, as well as the monitoring of disease progression. IsoPlexis specializes in cell-based proteomic systems and biomarkers, providing insights into functional protein biology and cellular signaling networks with high resolution. By offering these capabilities, the company aids in predicting patient responses to novel immunotherapies and cellular therapies, ultimately enhancing therapeutic development and informing clinical decisions.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

IsoPlexis is a life science technology company based in Branford, Connecticut, founded in 2013. It focuses on developing a single-cell detection system that identifies patient immune responses at the single-cell level. This innovative platform enables the assessment of therapeutic safety and efficacy, as well as the monitoring of disease progression. IsoPlexis specializes in cell-based proteomic systems and biomarkers, providing insights into functional protein biology and cellular signaling networks with high resolution. By offering these capabilities, the company aids in predicting patient responses to novel immunotherapies and cellular therapies, ultimately enhancing therapeutic development and informing clinical decisions.

Scipher Medicine is a biotechnology company that has developed a precision medicine platform aimed at improving drug therapy outcomes for patients with cardiovascular and autoimmune diseases. The company's flagship products, including PrismDx, PrismRA, and PrismUC, utilize molecular testing to predict patient responses to specific drug therapies, enabling healthcare providers to prescribe more effective treatments tailored to individual patient needs. For example, PrismRA identifies rheumatoid arthritis patients who are unlikely to respond to certain anti-TNF therapies, allowing for timely alternative treatments. By leveraging a simple blood sample to analyze RNA and generate genomic signatures, Scipher Medicine helps healthcare professionals select the most suitable therapies based on the underlying biology of diseases rather than relying on traditional classifications or symptomatic assessments. This innovative approach not only enhances patient care but also addresses significant inefficiencies in the healthcare system, reducing costs associated with ineffective treatments. Scipher Medicine, incorporated in 2013 and based in Waltham, Massachusetts, aims to transform drug prescribing and development through its advanced molecular technology.

908 Devices Inc. is a Boston-based company that specializes in the development and sale of handheld and desktop measurement devices for chemical and biochemical analysis. Founded in 2012, the company leverages mass spectrometry technology to create portable tools designed for immediate application in various fields, including life sciences research, bioprocessing, industrial biotechnology, and forensics. Its product lineup includes the MX908, a battery-powered, handheld mass spectrometry device capable of rapid analysis of unknown gas, liquid, and solid materials; the Rebel, a desktop analyzer offering real-time data on bioprocess environments; and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. 908 Devices aims to provide reliable and actionable insights in challenging environments, meeting the needs of professionals who require efficient solutions for complex analytical tasks.

Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

NanoView Biosciences is a biotechnology company that specializes in the development of technologies for the characterization of extracellular vesicles, particularly exosomes. Founded in 2015 and based in Boston, Massachusetts, the company utilizes its proprietary ExoView technology to provide high-throughput and cost-effective analysis solutions for life science researchers. NanoView's products, which include the ExoView R100 and ExoView tetraspanin, enable precise detection and multiparametric characterization of exosomes from complex biological samples such as blood, serum, plasma, and urine. In addition to its core products, the company offers custom assays, sample services, and a support platform to aid researchers in understanding the biological roles of exosomes and utilizing them as biomarkers for disease diagnosis, treatment, and monitoring.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Outcomes4Me Inc. is an AI-driven healthcare platform based in Cambridge, Massachusetts, founded in 2017. It focuses on empowering cancer patients by providing access to personalized, evidence-based treatment options and clinical information. The platform enables patients to navigate their care proactively, facilitating informed decision-making and improving health outcomes. By democratizing healthcare, Outcomes4Me promotes health equity and supports deeper insights into patient care, while also accelerating research and access to innovative treatments. The company is led by a team of experienced professionals from various sectors, including healthcare, oncology, and technology, dedicated to enhancing the patient experience in cancer treatment.